 Omar Khan
Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bariatric Surgery | 2 | 2020 | 162 | 1.040 |
Why?
| | Global Health | 2 | 2016 | 290 | 0.820 |
Why?
| | International Educational Exchange | 1 | 2016 | 11 | 0.540 |
Why?
| | Fractures, Bone | 1 | 2020 | 373 | 0.490 |
Why?
| | Maternal Death | 1 | 2013 | 8 | 0.450 |
Why?
| | Education, Medical, Undergraduate | 1 | 2016 | 179 | 0.450 |
Why?
| | Maternal Health Services | 1 | 2013 | 83 | 0.410 |
Why?
| | Schools, Medical | 1 | 2013 | 125 | 0.400 |
Why?
| | Quality Assurance, Health Care | 1 | 2013 | 315 | 0.380 |
Why?
| | Kidney Transplantation | 1 | 2016 | 559 | 0.350 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 944 | 0.340 |
Why?
| | Endpoint Determination | 1 | 2009 | 69 | 0.330 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2009 | 69 | 0.310 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2009 | 123 | 0.310 |
Why?
| | Health Promotion | 1 | 2013 | 690 | 0.290 |
Why?
| | Pelizaeus-Merzbacher Disease | 1 | 2006 | 3 | 0.270 |
Why?
| | Neuromyelitis Optica | 2 | 2017 | 114 | 0.240 |
Why?
| | Multiple Sclerosis | 3 | 2010 | 380 | 0.190 |
Why?
| | Network Meta-Analysis | 1 | 2020 | 17 | 0.180 |
Why?
| | Bayes Theorem | 1 | 2020 | 333 | 0.160 |
Why?
| | Capacity Building | 1 | 2016 | 51 | 0.130 |
Why?
| | Obesity | 2 | 2020 | 2523 | 0.130 |
Why?
| | Cultural Competency | 1 | 2016 | 73 | 0.130 |
Why?
| | Gastrectomy | 1 | 2016 | 83 | 0.130 |
Why?
| | Developing Countries | 1 | 2016 | 242 | 0.120 |
Why?
| | Brain | 1 | 2006 | 2372 | 0.120 |
Why?
| | Interpersonal Relations | 1 | 2016 | 342 | 0.110 |
Why?
| | Obesity, Morbid | 1 | 2016 | 199 | 0.110 |
Why?
| | Graft Rejection | 1 | 2016 | 533 | 0.100 |
Why?
| | Humans | 12 | 2020 | 115859 | 0.100 |
Why?
| | International Cooperation | 1 | 2013 | 175 | 0.100 |
Why?
| | Laparoscopy | 1 | 2016 | 400 | 0.100 |
Why?
| | Program Evaluation | 1 | 2016 | 841 | 0.100 |
Why?
| | Social Environment | 1 | 2013 | 287 | 0.100 |
Why?
| | Weight Loss | 1 | 2016 | 633 | 0.100 |
Why?
| | Immunologic Factors | 2 | 2010 | 219 | 0.090 |
Why?
| | Education, Medical | 1 | 2013 | 225 | 0.090 |
Why?
| | Neuroprotective Agents | 1 | 2010 | 105 | 0.080 |
Why?
| | Major Histocompatibility Complex | 1 | 2010 | 220 | 0.080 |
Why?
| | Twins, Monozygotic | 1 | 2010 | 210 | 0.080 |
Why?
| | Research Design | 1 | 2015 | 949 | 0.080 |
Why?
| | Sample Size | 1 | 2009 | 119 | 0.080 |
Why?
| | Stroke | 1 | 2017 | 1016 | 0.080 |
Why?
| | United States | 2 | 2016 | 12319 | 0.080 |
Why?
| | Genome, Human | 1 | 2010 | 372 | 0.080 |
Why?
| | Secondary Prevention | 1 | 2009 | 223 | 0.080 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 325 | 0.070 |
Why?
| | Curriculum | 1 | 2013 | 856 | 0.070 |
Why?
| | Fabry Disease | 1 | 2006 | 1 | 0.070 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 533 | 0.070 |
Why?
| | Demyelinating Diseases | 1 | 2006 | 75 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2010 | 2807 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 1871 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2010 | 2201 | 0.060 |
Why?
| | Myelin Sheath | 1 | 2006 | 145 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2010 | 2581 | 0.050 |
Why?
| | Female | 4 | 2017 | 60070 | 0.050 |
Why?
| | Adult | 3 | 2016 | 30814 | 0.040 |
Why?
| | Haplotypes | 2 | 2010 | 475 | 0.040 |
Why?
| | Middle Aged | 1 | 2016 | 27078 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1359 | 0.030 |
Why?
| | Male | 2 | 2016 | 56103 | 0.030 |
Why?
| | Glatiramer Acetate | 1 | 2010 | 20 | 0.020 |
Why?
| | INDEL Mutation | 1 | 2010 | 13 | 0.020 |
Why?
| | Allelic Imbalance | 1 | 2010 | 7 | 0.020 |
Why?
| | Calcineurin Inhibitors | 1 | 2010 | 59 | 0.020 |
Why?
| | Interferon-beta | 1 | 2010 | 80 | 0.020 |
Why?
| | CpG Islands | 1 | 2010 | 123 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2010 | 99 | 0.020 |
Why?
| | Breast | 1 | 2010 | 139 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2010 | 268 | 0.020 |
Why?
| | Heterozygote | 1 | 2010 | 254 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2010 | 157 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 220 | 0.020 |
Why?
| | Adjuvants, Immunologic | 1 | 2010 | 206 | 0.020 |
Why?
| | Genetics, Population | 1 | 2010 | 204 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4443 | 0.020 |
Why?
| | Quantitative Trait Loci | 1 | 2010 | 322 | 0.020 |
Why?
| | Alleles | 1 | 2010 | 817 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2010 | 633 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6434 | 0.020 |
Why?
| | DNA Methylation | 1 | 2010 | 502 | 0.020 |
Why?
| | Peptides | 1 | 2010 | 864 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2010 | 967 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2010 | 3054 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2004 | 0.010 |
Why?
| | Cohort Studies | 1 | 2010 | 4960 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2010 | 1872 | 0.010 |
Why?
| | Lung | 1 | 2010 | 3683 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2010 | 2206 | 0.010 |
Why?
| | Adolescent | 1 | 2010 | 17935 | 0.010 |
Why?
|
|
Khan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|